Tosedostat (CHR2797) is primarily investigated for its potential in cancer treatment, particularly in hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). It functions as an aminopeptidase inhibitor, disrupting protein degradation and amino acid recycling within cancer cells, leading to cell stress and apoptosis. Its application is focused on targeting cancer cells while minimizing damage to healthy tissues, making it a promising candidate for therapeutic use. Clinical trials have explored its efficacy as a monotherapy and in combination with other anticancer agents, aiming to improve outcomes for patients with refractory or relapsed diseases. Additionally, research suggests its potential in solid tumors, though further studies are needed to confirm its broader applicability.